UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 511

Sortiert nach

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

The Lancet (British edition), 2014-06, Vol.383 (9936), p.2213-2221

2014

Volltextzugriff (PDF)

Challenges of developing, conducting, analysing and reporting a COVID-19 study as the COVID-19 pandemic unfolds: an online co-autoethnographic study

BMJ open, 2021-06, Vol.11 (6), p.e048788

2021

Volltextzugriff (PDF)

Hyperacute stroke thrombolysis via telemedicine: a multicentre study of performance, safety and clinical efficacy

BMJ open, 2022-01, Vol.12 (1), p.e057372-e057372

2022

Volltextzugriff (PDF)

Carbon dioxide flushing versus saline flushing of thoracic aortic stents (INTERCEPTevar): protocol for a multicentre pilot randomised controlled trial

BMJ open, 2023-04, Vol.13 (4), p.e067605-e067605

2023

Volltextzugriff (PDF)

Anticholinergics for urinary symptoms in multiple sclerosis

Cochrane database of systematic reviews, 2009-01 (1), p.CD004193

2009

Volltextzugriff (PDF)

Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial

BMJ open, 2024-02, Vol.14 (2), p.e083582-e083582

2024

Volltextzugriff (PDF)

OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis

BMJ open, 2021-11, Vol.11 (11), p.e050176-e050176

2021

Volltextzugriff (PDF)

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

The Lancet (British edition), 2018-03, Vol.391 (10127), p.1263-1273

2018

Volltextzugriff (PDF)

Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis

Current medical research and opinion, 2020-07, Vol.36 (7), p.1157-1166

2020

Volltextzugriff (PDF)

The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis

Current medical research and opinion, 2020-07, Vol.36 (7), p.1145-1156

2020

Volltextzugriff (PDF)

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

The New England journal of medicine, 2012-09, Vol.367 (12), p.1098-1107

2012

Volltextzugriff (PDF)

Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility

Journal of medical economics, 2017-09, Vol.20 (9), p.962-973

2017

Volltextzugriff (PDF)

Primary care family physicians and 2 hospitalist models: comparison of outcomes, processes, and costs

The Journal of family practice, 2002-12, Vol.51 (12), p.1021-1027

2002

Volltextzugriff (PDF)

A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK

Journal of medical economics, 2017-05, Vol.20 (5), p.474-482

2017

Volltextzugriff (PDF)

Are frequent callers to family physicians high utilizers?

Annals of family medicine, 2004-11, Vol.2 (6), p.546-548

2004

Volltextzugriff (PDF)

Low-molecular-weight heparin in preventing and treating DVT

American family physician, 1999-03, Vol.59 (6), p.1607-1612

1999

Volltextzugriff (PDF)

Quinolones: a practical review of clinical uses, dosing considerations, and drug interactions

The Journal of family practice, 1996-01, Vol.42 (1), p.69-78

1996

Volltextzugriff (PDF)

Intussusception

American family physician, 1996-07, Vol.54 (1), p.213

1996

Volltextzugriff (PDF)

How should we manage infants at risk for group B streptococcal disease? (Clinical Inquiries: from the Family Practice Inquiries Network)

The Journal of family practice, 2003-05, Vol.52 (5), p.406

2003

Volltextzugriff (PDF)

Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial

The Lancet (British edition), 2020-04, Vol.395 (10233), p.1345-1360

2020

Volltextzugriff (PDF)

Ethics, economics, and the use of primaquine to reduce falciparum malaria transmission in asymptomatic populations

PLoS medicine, 2014-08, Vol.11 (8), p.e1001704

2014

Volltextzugriff (PDF)

Coronary CT Angiography and 5-Year Risk of Myocardial Infarction

The New England journal of medicine, 2018-09, Vol.379 (10), p.924-933

2018

Volltextzugriff (PDF)

Microvascular obstruction and endothelial activation are independently associated with the clinical manifestations of severe falciparum malaria in adults: an observational study

BMC medicine, 2015-05, Vol.13 (1), p.122-122, Article 122

2015

Volltextzugriff (PDF)

1 – 25 von 511

Suche als RSS-Feed

Aktive Filter

ThemaAnimals

ThemaRisk Factors

ThemaGeneral & Internal Medicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(496)
Mit Volltextzugriff
(428)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

Challenges of developing, conducting, analysing and reporting a COVID-19 study as the COVID-19 pandemic unfolds: an online co-autoethnographic study

Hyperacute stroke thrombolysis via telemedicine: a multicentre study of performance, safety and clinical efficacy

Carbon dioxide flushing versus saline flushing of thoracic aortic stents (INTERCEPTevar): protocol for a multicentre pilot randomised controlled trial

Anticholinergics for urinary symptoms in multiple sclerosis

Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial

OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis

The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility

Primary care family physicians and 2 hospitalist models: comparison of outcomes, processes, and costs

A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK

Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis

Are frequent callers to family physicians high utilizers?

Low-molecular-weight heparin in preventing and treating DVT

Quinolones: a practical review of clinical uses, dosing considerations, and drug interactions

Intussusception

How should we manage infants at risk for group B streptococcal disease? (Clinical Inquiries: from the Family Practice Inquiries Network)

Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis

Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial

Ethics, economics, and the use of primaquine to reduce falciparum malaria transmission in asymptomatic populations

Coronary CT Angiography and 5-Year Risk of Myocardial Infarction

Microvascular obstruction and endothelial activation are independently associated with the clinical manifestations of severe falciparum malaria in adults: an observational study

Aktive Filter

Suchergebnisse filtern